Climb Bio (CLYM) vs. The Competition Head-To-Head Review

Climb Bio (NASDAQ:CLYM) is one of 1,061 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Climb Bio to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Climb Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Analyst Ratings

This is a breakdown of recent ratings for Climb Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7867	21333	48983	1246	2.55

Climb Bio presently has a consensus price target of $10.00, indicating a potential upside of 378.47%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.16%. Given Climb Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than its peers.

Earnings and Valuation

This table compares Climb Bio and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-0.98
Climb Bio Competitors	$9.59 billion	$147.39 million	-5.65

Climb Bio’s peers have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Climb Bio has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500. Comparatively, Climb Bio’s peers have a beta of 3.65, suggesting that their average stock price is 265% more volatile than the S&P 500.

Insider and Institutional Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Climb Bio beats its peers on 7 of the 13 factors compared.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.